PASG PE Ratio & Valuation, Is PASG Overvalued

Historical Valuation

Passage Bio Inc (PASG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.33. The fair price of Passage Bio Inc (PASG) is between NaN to NaN according to relative valuation method.

Relative Value

Fair Zone

NaN-NaN

Current Price：8.51

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Passage Bio Inc (PASG) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Passage Bio Inc (PASG) has a current Price-to-Book (P/B) ratio of 1.19. Compared to its 3-year average P/B ratio of 0.51, the current P/B ratio is approximately 132.89% higher. Relative to its 5-year average P/B ratio of 0.70, the current P/B ratio is about 71.19% higher. Passage Bio Inc (PASG) has a Forward Free Cash Flow (FCF) yield of approximately -90.12%. Compared to its 3-year average FCF yield of -162.85%, the current FCF yield is approximately -44.66% lower. Relative to its 5-year average FCF yield of -132.34%, the current FCF yield is about -31.90% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PASG competitors is 20.59, providing a benchmark for relative valuation. Passage Bio Inc Corp (PASG.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PASG increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PASG in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PASG currently overvalued or undervalued?

What is Passage Bio Inc (PASG) fair value?

PASG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Passage Bio Inc (PASG) is between NaN to NaN according to relative valuation method.

How does PASG's valuation metrics compare to the industry average?

The average P/S ratio for PASG's competitors is 20.59, providing a benchmark for relative valuation. Passage Bio Inc Corp (PASG) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Passage Bio Inc (PASG) as of Mar 11 2026?

As of Mar 11 2026, Passage Bio Inc (PASG) has a P/B ratio of 1.19. This indicates that the market values PASG at 1.19 times its book value.

What is the current FCF Yield for Passage Bio Inc (PASG) as of Mar 11 2026?

As of Mar 11 2026, Passage Bio Inc (PASG) has a FCF Yield of -90.12%. This means that for every dollar of Passage Bio Inc's market capitalization, the company generates -90.12 cents in free cash flow.

What is the current Forward P/E ratio for Passage Bio Inc (PASG) as of Mar 11 2026?

As of Mar 11 2026, Passage Bio Inc (PASG) has a Forward P/E ratio of -1.42. This means the market is willing to pay $-1.42 for every dollar of Passage Bio Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Passage Bio Inc (PASG) as of Mar 11 2026?

As of Mar 11 2026, Passage Bio Inc (PASG) has a Forward P/S ratio of 0.00. This means the market is valuing PASG at $0.00 for every dollar of expected revenue over the next 12 months.

PASG Valuation